126 related articles for article (PubMed ID: 6690605)
21. The attack phase of human complement: differentiation between membrane binding and complex formation by the detection of neoantigen expression in situ. A morphometric immunoferritin study.
Balkarowa-Ständer J; Rother U; Rauterberg EW
J Immunol; 1981 Sep; 127(3):1089-93. PubMed ID: 7264298
[TBL] [Abstract][Full Text] [Related]
22. Effect of agents that produce membrane disorder on lysis of erythrocytes by complement.
Shin ML; Hänsch G; Mayer MM
Proc Natl Acad Sci U S A; 1981 Apr; 78(4):2522-5. PubMed ID: 6941304
[TBL] [Abstract][Full Text] [Related]
23. Membrane vesiculation of Naegleria fowleri amoebae as a mechanism for resisting complement damage.
Toney DM; Marciano-Cabral F
J Immunol; 1994 Mar; 152(6):2952-9. PubMed ID: 8144894
[TBL] [Abstract][Full Text] [Related]
24. On the mechanism of membrane damage by complement: the effect of length and unsaturation of the acyl chains in liposomal bilayers and the effect of cholesterol concentration in sheep erythrocyte and liposomal membranes.
Shin ML; Paznekas WA; Mayer MM
J Immunol; 1978 Jun; 120(6):1996-2002. PubMed ID: 659889
[No Abstract] [Full Text] [Related]
25. Complement membrane attack complex, perforin, and bacterial exotoxins induce in K562 cells calcium-dependent cross-protection from lysis.
Reiter Y; Ciobotariu A; Jones J; Morgan BP; Fishelson Z
J Immunol; 1995 Aug; 155(4):2203-10. PubMed ID: 7636268
[TBL] [Abstract][Full Text] [Related]
26. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
[TBL] [Abstract][Full Text] [Related]
27. Dynamic behaviour of amphiphilic lipids to penetrate into membrane of intact human erythrocytes and to induce change in the cell shape.
Fujii T; Tamura A
Biomed Biochim Acta; 1983; 42(11-12):S81-5. PubMed ID: 6675720
[TBL] [Abstract][Full Text] [Related]
28. Sublytic complement attack exposes C-reactive protein binding sites on cell membranes.
Li YP; Mold C; Du Clos TW
J Immunol; 1994 Mar; 152(6):2995-3005. PubMed ID: 8144898
[TBL] [Abstract][Full Text] [Related]
29. Quantitative studies on lysolecithin-mediated hemolysis. Use of ether-deoxy lysolecithin analogs with varying aliphatic chain-lengths.
Weltzien HU; Arnold B; Reuther R
Biochim Biophys Acta; 1977 May; 466(3):411-21. PubMed ID: 557991
[TBL] [Abstract][Full Text] [Related]
30. Cyanine dye fluorescence used to measure membrane potential changes due to the assembly of complement proteins C5b-9.
Wiedmer T; Sims PJ
J Membr Biol; 1985; 84(3):249-58. PubMed ID: 4032456
[TBL] [Abstract][Full Text] [Related]
31. Membrane stabilizing effect of lysolecithin in calf red blood cells.
Imre S; Horváth Z; Szilágyi T
Acta Physiol Acad Sci Hung; 1980; 55(2):113-20. PubMed ID: 7435204
[TBL] [Abstract][Full Text] [Related]
32. Interaction between complement proteins C5b-7 and erythrocyte membrane sialic acid.
Marshall P; Hasegawa A; Davidson EA; Nussenzweig V; Whitlow M
J Exp Med; 1996 Oct; 184(4):1225-32. PubMed ID: 8879193
[TBL] [Abstract][Full Text] [Related]
33. Incorporation of human complement C8 into the membrane attack complex is mediated by a binding site located within the C8beta MACPF domain.
Brannen CL; Sodetz JM
Mol Immunol; 2007 Feb; 44(5):960-5. PubMed ID: 16624411
[TBL] [Abstract][Full Text] [Related]
34. [Effect of cholesterol on the stability of human erythrocyte membranes to electric breakdown].
Goncharenko MS; Katkov II
Biofizika; 1985; 30(3):441-5. PubMed ID: 4027273
[TBL] [Abstract][Full Text] [Related]
35. Isolation of homologous restriction factor from human urine. Immunochemical properties and biologic activity.
Zalman LS; Brothers MA; Müller-Eberhard HJ
J Immunol; 1989 Sep; 143(6):1943-7. PubMed ID: 2476489
[TBL] [Abstract][Full Text] [Related]
36. Kinetics of polymerization of a fluoresceinated derivative of complement protein C9 by the membrane-bound complex of complement proteins C5b-8.
Sims PJ; Wiedmer T
Biochemistry; 1984 Jul; 23(14):3260-7. PubMed ID: 6432040
[TBL] [Abstract][Full Text] [Related]
37. Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps.
Ollert MW; Kadlec JV; David K; Petrella EC; Bredehorst R; Vogel CW
J Immunol; 1994 Sep; 153(5):2213-21. PubMed ID: 8051421
[TBL] [Abstract][Full Text] [Related]
38. Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis.
Pilzer D; Fishelson Z
Int Immunol; 2005 Sep; 17(9):1239-48. PubMed ID: 16091382
[TBL] [Abstract][Full Text] [Related]
39. Isolation of erythrocyte membrane inhibitor of reactive lysis type II. Identification as glycophorin A.
Tomita A; Radike EL; Parker CJ
J Immunol; 1993 Sep; 151(6):3308-23. PubMed ID: 7690802
[TBL] [Abstract][Full Text] [Related]
40. A reexamination of the role of clusterin as a complement regulator.
Hochgrebe TT; Humphreys D; Wilson MR; Easterbrook-Smith SB
Exp Cell Res; 1999 May; 249(1):13-21. PubMed ID: 10328949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
